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The aim of this study was to investigate the changes in transport and effectiveness of salbutamol 
sulphate (SAL) and budesonide (BD) following stimulation with transforming growth factor-β 
(TGF-β) in mono- and co-culture models of bronchial and alveolar epithelium. 
Primary bronchial and alveolar epithelial cells, grown at air interface on filters, either as 
monocultures or in co- culture with airway smooth muscle cells or alveolar macrophages, 
respectively, were stimulated with TGF-β. The biological response was modulated by depositing 
aerosolised SAL and BD on bronchial and alveolar models, respectively. Barrier integrity, 
permeability to fluorescein-Na, transport of the deposited drug and the pharmacological response 
to SAL (cAMP and IL-8 levels) or BD (IL-6 and -8 levels) were measured. 
While stimulation with TGF-β did not have any significant effect on the transepithelial electrical 
resistance and permeability to fluorescein-Na in mono- and co- culture models, transport of SAL 
and BD were affected in cultures from some of the patients (6 out of 10 for bronchial and 2 out 
of 4 for alveolar cells). The bronchial co-culture showed a better responsiveness to SAL in terms 
of cAMP release than the monoculture. In contrast, the difference between alveolar mono- and 
co-cultures to TGF-β mediated interleukin release and its modulation by BD was less 
pronounced.  
Our data point to intrinsic differences in the transport of, and responsiveness to, SAL and BD 
when epithelial cell cultures originate from different patients. Moreover, if the biological 
responses (e.g. IL-8, cAMP) involve communication between different cell types, co-culture 
models are more relevant to measure such effects than monocultures.
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1. Introduction 
Chronic obstructive pulmonary disease (COPD) and asthma are major and increasing health 
problems worldwide [1, 2] causing considerable morbidity and mortality. Despite the fact that 
asthma and chronic obstructive pulmonary disease (COPD) are both featured by airway 
remodelling and chronic inflammation of the airways, there are differences in the site of 
inflammation as well as the inflammatory cells involved, suggesting different patterns of 
mediators in each disease [3].  
β2-agonists and inhaled corticosteroids improve clinical outcome of COPD and asthma. The 
Global Initiative for Asthma (GINA) reports salbutamol sulphate (SAL) to be the most widely 
used short- and quick-acting airway bronchodilator, while budesonide (BD) is mentioned as one 
of the most effective anti-inflammatory inhaled corticosteroids (ICS) that markedly reduces the 
frequency and severity of asthma symptoms. Global Strategy for Diagnosis, Management, and 
Prevention of COPD (GOLD) reports the efficacy and safety of BD in the management of COPD 
[1, 2]. SAL binds to β2-adrenergic receptors on bronchial smooth muscle cells that 
consequentially result in the activation of adenylyl cyclase, and subsequent cyclic adenosine 
monophosphate (cAMP)-mediated smooth muscle relaxation [4]. However, BD exerts its anti-
inflammatory effect by suppressing the inflammatory gene transcription in asthma, COPD and 
other inflammatory diseases [5]. 
Remodelling, a well-known feature of severe asthma and COPD, involves many inflammatory 
and structural cells that release multiple mediators. The transforming growth factor-β (TGF-β) 
regulates cellular functions such as proliferation, apoptosis, differentiation, and migration. The 
regulatory role of TGF-β in airway remodelling has been shown in several studies [6, 7]. In 
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addition, TGF-β acts as a pro-fibrotic and immune-modulatory cytokine, is increased in patients 
with severe diseases such as COPD and has been shown to play a pivotal role in airway 
structural changes [8]. Macrophages, as well as airway and alveolar epithelial cells, may be an 
important source of inflammatory mediators, including TGF-β, which in turn stimulates the 
synthesis of extra cellular matrix components leading to local fibrosis [9, 10]. It has also been 
shown that TGF-β down regulates the β2-adrenergic receptors, attenuating the effects of 
therapeutically applied β2-adrenergic agonists [10, 11]. 
In patients with COPD and asthma, the preferable route of administration for the β2-agonists and 
steroids is via inhalation. When drug microparticles are aerosolised and inhaled, they deposit at 
different regions of the airways on epithelial cells. In order for these drugs to be therapeutically 
effective they then need to be transported through the bronchial epithelial cell layer to reach the 
underlying mesenchymal and inflammatory cells. In clinical practice it is common to 
progressively increase the dose of steroids in an attempt to control the disease. However, in 
steroid insensitive patients, this often results in long-term treatment with high doses of steroids, 
causing significant side effects [12, 13]. Hence, understanding the reason behind insensitivity to 
corticosteroids is crucial. There are many plausible reasons why steroids are ineffective in COPD 
and severe asthma. Hence, the majority of research has focused either on elucidating the 
molecular mechanisms behind those diseases or on measuring the therapeutic outcome in clinical 
settings [14-19]. The use of advanced in vitro models based on human cells and tissues for 
investigating the mechanisms, safety and efficacy of therapeutic modalities is rather new, but 
may significantly facilitate the translation of new, safe, and better medicines into the clinic. The 
recently published review of Hittinger et al. focuses on this topic and offers a broad overview of 
preclinical in vitro models [20]. 
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In the last decade, transport of drug molecules across primary airway epithelial cells and 
respiratory epithelial cell lines have been used to determine the fate of drug microparticles after 
deposition on airway epithelia [20-22]. A previous study by the author has reported that the 
transport of steroids through lung epithelial cell lines is markedly ineffective [23], which led to 
the hypothesis that epithelial remodelling in COPD and asthma may contribute in exacerbations 
and unresponsiveness to standard β2-agonist and corticosteroid therapy, due to changes in 
epithelial cell permeability and in cytokine secretion. 
The aim of this study was to investigate mono- and co-culture models representing the 
characteristics of the bronchial and alveolar epithelium following stimulation with TGF-β to 
allow monitoring relevant pathological changes upon pro-inflammatory stimuli, such as TGF-
β, as well as their modulation by SAL and BD.  
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2. Experimental Section 
Human bronchial epithelial (hBE) and airway smooth muscle (ASM) cell isolation and 
culture 
hBE and ASM cell isolation 
Bronchial epithelial and ASM cells were isolated from human bronchial airways obtained from 
patients undergoing lung resection or transplantation. hBE cells were maintained and expanded 
separately in Ham’s F-12 with growth supplements, while ASM cells were maintained in DMEM 
supplemented with 10% FBS as previously described [24]. The Ethics Review Committee of the 
South West Sydney Area Health Service, Royal Prince Alfred Hospital and the University of 
Sydney Human Research Ethics Committee provided approval for the experiments. 
Air- interface culture of hBE cells 
Bronchial epithelial cells at passage 2 or 3 were seeded onto Transwell® polyester inserts (0.33 
cm2, 0.4 µm pore size) (Corning Costar, Lowell, MA, USA) (density: 3×105 cells per insert). The 
growth medium in the apical chamber was removed when the cells were confluent and the 
bronchial epithelial growth medium (BEGM) (Lonza, Melbourne, Australia) in the basal 
chamber was replaced by bronchial epithelial differentiation medium (BEDM) (Lonza, 
Melbourne, Australia). hBE cells were allowed to differentiate under air-interface over 21-28 
days. Differentiation was confirmed through mucus secretion and cilia formation and beating 
(see supplementary materials). 
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Co-culture of hBE cells and ASM cells 
21 days following of seeding of hBE cells on Transwells®, passages 3-7 of the ASM cells 
derived from the same patient were seeded in 24-well culture plates (density of 3.2 × 104 
cells.ml-1) in DMEM supplemented with 10% FBS. Three days post seeding, the Transwells® 
containing differentiated hBE cells were moved to the plates containing ASM cells (marking the 
day 0 of the co-culture) and the co-culture was maintained in the BEDM media for 72 hours 
before further experiments were conducted. 
Alveolar epithelial and macrophage cell culture 
Alveolar epithelial and alveolar macrophage cell isolation and culture 
Non-tumor lung tissue from patients undergoing lung rescission was received from the Heart 
Center Voelklingen. The use of human tissue was approved by the local ethic committee (State 
Medical Board of Registration, Saarland, Germany). 
The isolation of alveolar epithelial type II cells was performed according to an established 
protocol [25]. Tissue cubes with an edge length of 5 µm were isolated from the lung tissue and 
washed three times in buffer (137 mM NaCl, 5 mM KCl, 0.7 mM Na2HPO4, 10 mM HEPES, 5.5 
mM glucose, pH 7.4) with a cell strainer (100 µm pore size; Becton Dickinson, Heidelberg, 
Germany). Alveolar macrophages from the first filtrate were further incubated as described 
below. 
Lung tissue was digested in a Trypsin solution for 40 minutes at 37°C (Sigma Aldrich; 
Taufkirchen, Germany). In order to remove tissue macrophages and erythrocytes, cells were 
incubated on cell culture petri-dishes to for 90 minutes followed by a percoll gradient (Sigma 
Aldrich, Taufkirchen, Germany). The alveolar type II cells were purified with an EPCAM-
antibody (Miltenyi, Bergisch-Gladbach, Germany). Finally, cells were seeded on Snapwell™-
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inserts with a pore size of 0.4 µm (Corning, Schiphol-Rijk, the Netherlands), which were treated, 
with a mixture of fibronectin (Becton Dickinson, Heidelberg, Germany) and collagen (Sigma 
Aldrich, Taufkirchen, Germany). Cells were cultured in SAGM (Lonza; Verviers, Belgium) for 4 
days until the co-culture was initialised. 
 
Alveolar macrophages were washed with RPMI medium containing 5% FCS and 1%P/S, 
distributed on three cell culture petri dishes and further incubated for one hour. Cells were again 
washed three times with buffer and incubated in RPMI. Medium was changed after one day and 
the cells were cultured until day 4 (day 0 is the day of the isolation). 
Alveolar epithelial and alveolar macrophage co-culture 
The co-culture was prepared according to an established protocol by Hittinger et al. (manuscript 
in preparation [26]). Human alveolar macrophages and epithelial cells were isolated from the 
same donor as described above. 300,000 epithelial cells/cm² were seeded on a Transwell™-
membrane and cultured until day 4 (day 0 is the day of isolation). Meanwhile, the macrophages 
were kept on petri dishes in RPMI-medium. In order to remove the macrophages from the petri 
dish, cells were washed 3x in PBS and incubated for 10 minutes in Trypsin/EDTA. Cells were 
detached with a cell scraper, washed in RPMI 1x and counted with a Neubauer-chamber. 
100,000 alveolar macrophages/cm² in RPMI medium were placed on 300,000 alveolar type I-like 
cells on day 4 of culture. This procedure ensures that the epithelial cells form a tight barrier and 
macrophages are on top of the co-culture.  
For air-liquid interface culture, the protocol was adjusted as macrophages do not perform strong 
adherence on the epithelial cells and medium cannot be simply removed from a submerged 
culture. In order to overcome this issue, macrophages were counted with a Neubauer-chamber 
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and concentrated via centrifugation step to a small pellet. RPMI-medium was added to reach a 
final concentration of 100,000 macrophages in 6 µl RPMI-medium (for example: 2 x 106 
macrophages were centrifuged, the supernatant carefully removed and 120 µl RPMI medium 
added). 6 µl of the high concentrated cell suspension were carefully dropped in the middle of 
each Snapwell™-insert (1.12 cm² surface area) on day 4. Cells immediately spread over the 
whole surface and were incubated over night before performing the experiments. 
In both cases, submerged and air-liquid culture conditions, the co-culture was established on day 
4 and experiments were performed on day 5.  
 
Stimulation of the culture models with TGF-β 
TGF-β1 (Invitrogen, Sydney, Australia) was added to the basal chambers at concentration of 1 
ng/ml and 10 ng/ml to stimulate the hBE cells, hAEpC and co-culture setups (hBE and ASM 
cells as well as hAEpC and AM, respectively). In the monoculture of hBE cells, TGF-β was 
added following differentiation (21 to 28 days in culture); in the co-culture of hBE &ASM, TGF-
β was added following the third day of co-culture setup. The culture media in the basal chamber 
was sampled after 24 hours to measure the concentration of IL-8 using enzyme-linked 
immunosorbent assay (ELISA) kit (Becton Dickinson, Sydney, Australia) according to the 
manufacturer’s protocol. Samples of the untreated mono- and co-cultures were taken as control. 
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Barrier integrity measurements 
Transepithelial electrical resistance was measured using a EVOM voltohmmeter (World 
Precision Instruments, Sarasota, FL, USA) according to the method previously described [27]. 
Measurements were taken at 24 hours following stimulation with different concentrations of 
TGF-β in the bronchial and alveolar mono- and co-culture systems to monitor the integrity of 
barrier over time following treatment with TGF-β.  
TEER measurements were further confirmed by measuring the permeability of the paracellular 
marker fluorescein-Na (flu-Na) (Sigma-Aldrich, Sydney, Australia). The method for this study 
has been described elsewhere [27].  
 
Drug deposition on bronchial and alveolar epithelial cells 
Deposition of SAL on hBE cells 
The Twin stage impinger (TSI) (Radleys, Essex, UK) was used to deposit SAL from Ventolin 
Rotacaps (GSK, Victoria, Australia) on the untreated and stimulated hBE cells grown on 
Transwells®. The TSI was modified, as described previously by Grainger et al., to accommodate 
the Transwells® [28]. Following deposition of SAL, the Transwells® were transferred to a 24-
well plate containing 350 µl of fresh pre-warmed Hank's Balanced Salt Solution (HBSS) (Gibco, 
Invitrogen, Sydney, Australia). At set time points (10, 30, 60, 120, 180 and 240 mins) samples 
were taken from the basal chamber and the amount of SAL in the samples analysed using high 
performance liquid chromatography. 
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Deposition of BD on AE cells and AM 
The pharmaceutical aerosol deposition device on cell culture (PADDOCC) was used as 
described previously [29] to deliver BD from Budesonide Cyclocaps (Caelo, Hilden, Germany) 
to the pre-treated, unstimulated and stimulated hAEpC or co-cultures of hAEpC and AM grown 
on Snapwells™. Six days after seeding hAEpC (24 hours following co-culture with AM), the 
Snapwells™ were fitted into the PADDOCC and BD microparticles were deposited on the 
culture of the hBE cells or the co-culture. The Snapwells™ were then transferred to a 6-well 
plate containing 800 µl of HBSS. Samples (1, 3 and 5 hour) were assayed from the basal 
chamber and the amount of BD was analysed using validated high performance liquid 
chromatography method. 
 
Quantification of drugs in the samples 
Chemical analysis of SAL was performed with high performance liquid chromatography 
(HPLC), using a Shimadzu Prominence UFLC system equipped with an SPD-20A UV-Vis 
detector (Shimadzu Corporation, Japan) and NovaPak C18 column (5 µm, 150 × 3.9 mm) 
(Waters Corporation, Milford Massachusetts, USA). The mobile phase was a mixture of 
methanol and sodium phosphate monobasic dihydrate (30/70%, v/v) (pH 3.2). Flow rate, 
injection volume and detection wavelength were 1 ml.min-1, 100 µl and 276 nm, respectively.  
Quantification of BD was measured using UltiMate®3000 system (Dionex, Idstein, Germany) 
equipped with a reversed phase C18 Column (5µm, 4.6 × 250 mm) (Merck KGaA, Darmstadt, 
Germany). The mobile phase consisted of a mixture of phosphate buffer (pH 3) and acetonitrile 
(60:40%, v/v) delivered at a flow rate of 1.9 ml.min-1. The injection volume was 100 µl and BD 
was detected at 240 nm. 
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Measurement of pharmacological response to SAL and BD in untreated and stimulated 
cultures 
Measurement of cAMP production in culture of hBE and ASM cells 
In the co-culture model of hBE and ASM cells, following deposition of SAL using the TSI, the 
Transwells® containing the hBE cells were returned to the 24-well plates containing the ASM 
cells. ASM cells were lysed after 4 hours of experiment and the amount of cAMP was analysed 
using a cAMP ELISA assay kit (Perkin Elmer, Massachusetts, USA) according to the 
manufacturer’s protocol. 
Furthermore, monoculture of ASM cells were exposed to similar concentration of SAL in the 
basal chamber following 4 hours of transport study and the concentration of cAMP produced was 
analysed and compared to the cAMP concentration produced by ASM cells in the co-culture 
condition. 
Measurement of IL-8 and IL-6 production in culture of hAEpC and AM 
In alveolar mono- and co-culture setups, TGF-β was added to the basal chamber at the fifth day 
of culture setup and samples of the culture medium were taken 24 hours following stimulation 
with TGF-β  ELISA kit (life technologies, Karlsruhe, 
Germany). The concentrations of IL-6 and -8 in the media (basal chamber) of the unstimulated 
and TGF-β stimulated cells were compared with the IL-6 and -8 concentrations of unstimulated 
and TGF-β stimulated of the same cell culture setups 24 hours following deposition of BD. 
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Furthermore, results were compared to IL-6 and -8 concentrations from the alveolar cells pre-
treated with 1 µM BD on the fifth day of seeding followed by TGF-β stimulation day 6. The 
samples were taken 24 hours after stimulation to investigate the preventive anti-inflammatory 
role of BD in TGF-β stimulated cells. 
 
Statistical analysis of data 
Data were analysed using GraphPad Prism 6.0 software (GraphPad Software, San Diego, USA) 
and presented as mean ± standard deviation (SD). KS normality test defined the results to be 
normally distributed. Statistical significance was determined by paired t-test, one-way analysis of 
variance (ANOVA) or two-way ANOVA comparison test, where appropriate. All p values of 
less than 0.05 were considered significant. 
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Results 
Effect of TGF-β on hBE and ASM cells in vitro 
Transepithelial electrical resistance 
The TEER value of the hBE cells cultured for 21-28 days at air-interface configuration was 459 
± 27 Ω•cm2. Similar values were measured for the culture of hBE and ASM from the same 
patients after 3-4 days of co-culture (422 ± 35 Ω•cm2). In the monoculture of hBE cells, 
stimulation with 10ng/ml TGF-β resulted in a significant increase in TEER values (p ≤ 0.05) 
while a significant increase in TEER values of the co-culture (p ≤ 0.05) was observed only when 
the cells were stimulated with 1 ng/ml TGF-β.  
In general, the TEER values of co-cultures were slightly lower than monocultures of cells 
isolated from the same patients. Furthermore, there was a significant difference observed in 
TEER values of mono- and co- cultures following stimulation with 10 ng/ml TGF-β with the 
values measured (521 ± 27 Ω•cm2) and (451 ± 37 Ω•cm2) for mono- and co-culture, respectively 
(p ≤ 0.05). Figure 1a shows the change in TEER following exposure to different concentrations 
of TGF-β in mono- and co- cultures over 24 hours. 
 
Flu-Na paracellular permeability  
The permeability to flu-Na for both mono- and co-culture is shown in Figure 1b. For mono- and 
co- culture systems, permeability of the untreated cells were measured to be (4.1 ± 2.3) × 10-6 
cm.s-1 and (4.7 ± 1.0) × 10-6 cm.s-1, respectively. No significant difference was observed between 
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the permeability of the mono- and co- culture systems in control conditions and following 
stimulation with TGF-β at 1 and 10 ng/ml concentrations (p ≥ 0.05). 
 
Figure 1. a) TEER and b) paracellular permeability values of the mono- and co- culture of hBE 
and hBE & ASM cells to flu-Na, (n=5, hBE and ASM were isolated from the same patients) in 
the absence and presence of TGF-β (24 hours stimulation, 1 ng/ml and 10 ng/ml). 
 
Transport of SAL across hBE cells in mono- and co-culture setups 
Transport of SAL across hBE cells in the mono- and co-culture setting is depicted in Figure 2. In 
general, there was no significant difference (p ≥ 0.05) between the average percentages of SAL 
transported across TGF-β stimulated (48.47 ± 8.12%) vs. untreated hBE cells (54.46 ± 15.05%). 
In contrast to monoculture transport result, in the co-culture setup stimulation with TGF-
β resulted in a significant difference (p ≤ 0.05) in the average percentage of SAL transported 
across hBE cells with the values measured (56.53 ± 10.26%) and (45.12 ± 8.19%) for untreated 
and TGF-β , respectively. 
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Comparison between untreated and TGF-β stimulated cultures of individual patients cells 
revealed that cells from some patients responded more dramatically (p ≤ 0.05) to stimulation 
with TGF-β over 24 hours, while in other patients TGF-β stimulation did not reduce the transport 
significantly (p ≥ 0.05). 
 
Figure 2. Epithelial transport of Salbutamol (SAL) across: A) monocultures of hBE (n=12), B) 
co-cultures of hBE & ASM cells (n=5, hBE and ASM were isolated form the same patients) in 
the absence and presence of TGF-β (24 hours stimulation, 10 ng/ml). 
 
Effect of TGF-β on IL-8 production in mono- and co- culture setups 
Following stimulation of the mono- and co-cultures with TGF-β, samples of the culture media in 
the basal chamber were analysed and the amount of IL-8 produced was determined by ELISA. 
Without such stimulation, IL-8 was not significantly different between the monoculture and the 
co-culture systems, with the values measured being 165 ± 53 pg/ml and 189 ± 58 pg/ml, 
respectively (p ≥ 0.05).  
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Following 10ng/ml TGF-β stimulation, the monoculture of hBE cells showed a significant 
reduction of the IL-8 production (91 ± 30 pg/ml), whereas in the co-culture model stimulation 
with 1 ng/ml and 10 ng/ml TGF-β resulted in a significant increase in IL-8 secretion to 280 ± 60 
pg/ml and 290 ± 31 pg/ml, respectively (p ≤ 0.05) (Figure 3). 
 
Figure 3. Changes in IL-8 expression level in cultures of hBE, hBE & ASM and ASM cells 
(n=5, hBE and ASM were isolated form the same patients) in the absence and presence of TGF-
β (24 hours stimulation, 1 ng/ml and 10 ng/ml). 
 
Effect of TGF-β on pharmacological responsiveness to SAL in mono- and co- culture setups 
The pharmacological response to the same concentration of SAL, either resulting after transport 
across hBE cells to the basolateral chamber or after direct application of the corresponding 
amount of SAL to the supernatant of the mono-culture of ASM cells was measured via cAMP 
production. The cAMP concentration was 8.1 ± 1.0 nM in monoculture of ASM and 7.8 ± 1.0 
nM in the co-culture model. No significant difference was observed in mono- vs. co- culture 
condition (p ≥ 0.05) (Figure 4, black bars). 
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In comparison, upon 24 hours stimulation with TGF-β, the response to SAL (as reflected by the 
cAMP concentrations in the culture media) was significantly decreased in both culture setups to 
the average of 3.2 ± 1.0 nM in co-culture and 6.5 ± 1.0 nM in ASM monoculture (p ≤ 0.05) 
(Figure 4, white bars), indicating the influence of TGF-β in non-responsiveness to SAL. 
 
Figure 4. SAL-induced cAMP in culture of airway smooth muscle cells (mono- and co-culture 
setups) (n=5, hBE and ASM were isolated form the same patients) in the absence and presence 
of TGF-β (24 hours stimulation, 10 ng/ml). 
 
Effect of TGF-β on hAEpC and AM in vitro 
Transepithelial electrical resistance 
The TEER values measured for the monoculture of hAEpC and co-culture of hAEpC and AM at 
day 6 post seeding and 24 hours following co-culture are shown in Figure 5a. When comparing 
TEER values from all patients, there was no statistical significance when comparing mono- to 
co-culture (p ≥ 0.05) (431 ± 30 Ω•cm2 for monoculture vs. 417 ± 22 Ω•cm2 for co-culture). 
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Furthermore, stimulation with TGF-β (1 ng/ml and 10 ng/ml) for 24 hours did not significantly 
alter the TEER (p ≥ 0.05). Similar as previously found for hBE culture, cells obtained from the 
same patient showed a consistent increase in TEER value following stimulation with TGF-β 
compared to the non-stimulated control regardless of mono- or co-culture conditions (data not 
shown).  
 
Flu-Na paracellular permeability  
In general, results from the permeability studies were in good agreement with the TEER values 
obtained. For cells derived from each patient, there was no significant difference in permeability 
of the co-culture compared to the monoculture (p ≥ 0.05). Furthermore, treatment of the alveolar 
mono- and co- culture models with 10 ng/ml TGF-β did not result in a significant change in the 
permeability to flu-Na ((4.1 ± 1.00) × 10-6 cm.s-1 in untreated and (3.4 ± 0.45) × 10-6 cm.s-1) in 
stimulated co-cultures and ((3.5 ± 0.7) × 10-6 cm.s-1 in untreated and (2.7 ± 0.6) × 10-6 cm.s-1) in 
stimulated monocultures. Figure 5b shows the permeability of untreated and TGF-β stimulated 
hAEpC and the co-culture of hAEpC and AM. 
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Figure 5. a) TEER and b) paracellular permeability of the mono- and co- culture of hAEpC and 
hAEpC & AM to flu-Na (n=4, hAEpC and AM were isolated from the same patient) in the 
absence and presence of TGF-β (24 hours stimulation, 1 ng/ml and 10 ng/ml). 
 
Transport of BD across hAEpC in mono- and co- culture setups 
Figure 6 shows the percentage of BD transported following deposition on the unstimulated and 
stimulated mono- and co-culture setups. The results demonstrate that transport of BD across 
alveolar epithelial cells was not significantly different in mono- and co- culture systems (p ≥ 
0.05). Furthermore, no statistically significant change was observed in the average value of BD 
transport across both alveolar culture setups following 24 hours treatment with TGF-β (p ≥ 0.05).  
 
 
Figure 6. Epithelial transport of BD across a) monocultures of hAEpC, b) co-cultures of hAEpC 
& AM (n=4, hAEpC and AM were isolated form the same patients) in the absence and presence 
of TGF-β (24 hours stimulation, 10 ng/ml). 
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Effect of TGF-β on IL-6 and IL-8 production in mono- and co- culture systems 
Figure 7a and 7b show the concentration of IL-6 and -8 as a result of stimulation with TGF-β 
and, its modulation by BD. 
In the hAEpC monoculture and co-culture setup, stimulation with TGF-β (10 ng/ml)(white bars) 
increased the IL-6 concentration significantly (p ≤ 0.05), compared to the IL-6 levels from 
unstimulated cells (black bars) (for monoculture the IL-6 level increased significantly from 186 
± 39 pg/ml to 528 ± 99 pg/ml; in co-culture setup the value was increased from 301 ± 41 pg/ml 
to 790 ±120 pg/ml). Furthermore, the IL-6 level was significantly lower in the culture of the cells 
(both hAEpC monoculture and co-culture) pre-treated with 1 µM BD prior to stimulation (grey 
bars) in comparison with the stimulated cells (white bars) (p ≤ 0.05). The significant decrease 
was also observed when BD was deposited 24 hours post TGF-β stimulation (p ≤ 0.05). This 
indicates the capability of BD in maintaining and reducing the IL-6 concentration at control 
level. 
 
Furthermore, the difference observed in IL-6 levels produced in hAEpC monoculture and the co-
culture setup following stimulation was also significant (p ≤ 0.05). In the monoculture of AM 
alone, the changes in IL-6 levels were not statistically significant following stimulation, pre-
treatment and BD treatment of the AMs and IL-6 levels were measured to be significantly lower 
in the AM monoculture in comparison with the co-culture model following stimulation and BD 
treatment (p ≤ 0.05). 
 
In the monoculture of hAEpC, the significant change was only observed between the IL-8 levels 
in cells stimulated with TGF-β (white bars) (129 ± 21 pg/ml) and the cells pre-treated with 1 µM 
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BD (grey bars) (84 ± 18 pg/ml) (p ≤ 0.05). In the co-culture setup, however, IL-8 level from the 
cells stimulated with TGF-β  (white bar) (127 ± 23 pg/ml) was significantly lower than the 
unstimulated cells (black bar) (195 ± 25 pg/ml) (p ≤ 0.05) and was measured significantly higher 
than the cultures pre-treated with 1 µM BD (grey bar) (65 ± 9 pg/ml) (p ≤ 0.05) and treatment 
with BD following 24 hours of stimulation did not impact the amount of IL-8 expressed (p ≥ 
0.05). In the monoculture of AM, a significant reduction was observed in IL-8 levels in the 
cultures pre-treated with BD (grey bars) and the IL-8 levels in unstimulated (black bars) and 
TGF- β  stimulated cells (p ≤ 0.05). 
 
 
Figure 7. Changes in a) IL-6 and b) IL-8 expression level in cultures of hAEpC and hAEpC & 
AM in the absence of TGF-β (black bars), following 24 hours stimulation with TGF-β (10 
ng/ml) (white bars), pre-treatment with 1 µM BD prior to stimulation with TGF-β (grey bars) 
and treatment with BD following stimulation with TGF-β 
(n=4, hAEpC and AM were isolated form the same patients).
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Discussion 
This is the first study to compare mono- and co- culture models of primary bronchial (co-
cultured with ASM) and alveolar epithelial cell (co-cultured with AM) models as barrier to drug 
transport while simultaneously investigating the therapeutic effectiveness of the drugs following 
stimulation with TGF-β.  
Our results demonstrated that the permeability and TEER values of the untreated cells for both 
bronchial and alveolar mono- and co- culture models were similar, and no significant difference 
was observed in the measurements. In the bronchial cells cultures, stimulation with TGF-β over 
24 hours resulted in a significant increase in TEER, while no significant change was observed in 
paracellular permeability. This finding indicates that while TEER and paracellular permeability 
of the air-interface cultured epithelial cells from bronchial and alveolar regions of the lung are 
not significantly different, they respond differently to TGF-β stimulation.  
 
The average transport of SAL across untreated hBE cells in mono- and co-culture settings was 
not significantly different. However, the percentage of SAL transported varied between 38 to 
78% of the deposited dose in epithelial cultures obtained from different patients. A more detailed 
analysis of individual patients’ cells revealed that the differences observed were not relevant to 
the background disease, age, sex or smoking history of the patients but rather pointing to the 
importance of inter-individual differences. Furthermore, stimulation with TGF-β in bronchial co-
culture setup resulted in an overall significant decrease of SAL transport. Similarly, in the 
alveolar mono- and co- culture models, transport of BD across untreated cells was not 
significantly different and the percentage of transport was measured to be between 65 to 90% of 
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the deposited dose of the drug. Stimulation with 10 ng/ml TGF-β did not significantly impact BD 
transport across the hAEpC in mono- or co-culture setup. 
It was observed that in unstimulated and TGF-β stimulated bronchial and alveolar mono- and co-
cultures, transport of SAL and BD ranged between 38 to 78% and 65 to 90%, respectively. One 
possible explanation could be the inter-individual difference in the membrane transporters 
expressed on the epithelial cells. It has been shown that transport of SAL is mediated via passive 
diffusion as well as the transporter proteins (i.e. organic cationic transporters-OCTs) [21, 30], 
while BD being lipophilic is transported by passive diffusion [31]. Furthermore, BD is known to 
be a substrate of P-glycoprotein [32], an efflux transporter that limits BD absorption by pumping 
it back into the airways. Therefore, the inter-individual differences in P-glycoprotein could have 
contributed to the differences in BD absorption. Interestingly, the inter-individual differences are 
also observed following stimulation with TGF-β  in the bronchial and alveolar cultures and the 
percentage of drug transported was affected more dramatically in some patient’s cells.  
Furthermore, the results demonstrated that TGF-β stimulation of the bronchial co-culture 
resulted in a significant decrease in SAL transport. In a previous study by Unwalla et al. [33] that 
reported the paracellular route was the major contributor to SAL flux across the airway 
epithelium. While a decrease in SAL transport following stimulation confirms the previous 
study, there was no evidence of a significant decrease in paracellular permeability or significant 
increase in TEER. This could be attributed to the fact that the mentioned study was conducted 
using tracheal epithelial cells from two subjects, while in the current study bronchial cells from 
more subjects were studied, which provided a superior representation of the biological 
variability.  
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β2-adrenergic receptor (β2-AR) agonists such as SAL are important for symptomatic 
management of airway obstruction and their effectiveness is affected by their transport across the 
epithelial barrier to get to the β2-AR on ASM cells. Reduced cAMP production and reduction in 
the number of β2-AR were reported to be the result of reduced responsiveness of ASM cells 
following treatment with TGF-β [34]. In this study a reduced cAMP release upon treatment of 
TGF-β stimulated cells by SAL was observed in the hBE-ASM and ASM cultures, although the 
decrease was more dramatic in the hBE & ASM co-cultures. In addition, in the present study the 
inter-individual differences observed in transport of SAL could have contributed to the cAMP 
levels observed. 
Corticosteroids such as BD are the most effective therapy targeting airway inflammation in 
asthma and COPD [1, 2], However, COPD is a disease characterised by steroid insensitivity, and 
some patients with asthma, especially those with severe disease are also refractory to steroid 
treatment [35]. Reduction in the transport of BD in some patients following stimulation with 
TGF-β, as observed in present study, could result in the interindividual differences in the amount 
of BD transported.  
In a previous study by Ge et al., [36] it was demonstrated that stimulation of hBE cells with 
TGF-β1 (1 ng/ml) resulted in a significant decrease in IL-8 levels. While in the present study the 
decrease in IL-8 levels measured in monoculture of hBE, hAEpC and co-culture of hAEpC & 
AM are in agreement with Ge et al., in the bronchial co-culture model (hBE & ASM), TGF-β 
caused a significant increase in IL-8 levels.  
Cell culture models of bronchial and respiratory epithelium have been developed to provide a 
platform for studying drug transport and uptake. While the longer established 2D monocultures 
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of epithelial cells are more suitable for high throughput screening, easier to use and less costly, 
they are on the other hand more reductionist and therefore less suitable to perform mechanistic 
studies or to investigate pathophysiological processes. Due to their reduced complexity mono-
cultures are less suitable to monitor changes in epithelial barrier properties as a result of 
respiratory diseases and do not take into account the role of other local cell types in the fate and 
therapeutic effectiveness of drugs. Novel advanced 3D models of the pulmonary epithelia that 
also comprise other cell types have recently been described [36, 37], reflecting the necessary 
cellular crosstalk when addressing questions of toxicity, transport or inflammatory responses. 
Thereby, the use of complex co-culture systems compared to monocultures has a clear influence 
on the study outcome. Kasper et al [37] demonstrated that a pulmonary epithelial-endothelial co-
culture was less responsive to silica nanoparticles in terms of toxicity, while inflammatory 
mediators (IL-8) were increased in the co-culture setup. In case of bronchial and alveolar models 
of hBE and hAEpC in the current study, unstimulated mono- and co-cultures did not show 
significantly different responses in terms of transport and cytokine secretion, while the bronchial 
stimulated co-culture was able to reflect the non-responsiveness to SAL and the alveolar 
simulated cultures showed a significant reduction in inflammatory cytokine levels following BD 
treatment. This finding indicates the requirement for a pathophysiological stimulus when 
investigating the efficacy of therapeutic drugs. 
The present study highlights the differences of monocultures vs. more complex co-cultures of 
different cell types and the importance of the cellular network, when biological responses (e.g. 
IL-8) and therapeutic effectiveness (e.g. cAMP) are studied. 
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Conclusion 
Taken together, the data from this study identifies that there might be intrinsic differences in the 
transport of SAL and BD in different patients that could manifest as clinically different responses 
to the drugs. Furthermore, the results of this study demonstrated the advantage of the co-cultures 
over monocultures and highlighted the impact of cellular interplay on the biological responses 
and therapeutic effectiveness of drug molecules. 
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